PRESS-RELEASE filed Jul 28, 2026 at 16:15 ET
Chemed reported Q2 2026 GAAP EPS of $5.13 (up 43.7% YoY) and revenue of $673.3M (up 8.8% YoY), beating consensus estimates of $5.60 EPS and $665.0M revenue by 0.9% and 1.2%, respectively. The beat was driven by VITAS's strong performance, with revenue up 11.9% and a sharp reduction in Medicare Cap billing limitations ($0.5M vs $16.4M last year). Guidance was raised meaningfully, with full-year adjusted EPS now $25.00-$25.75 (up from $24.00-$24.75), and VITAS ADC/revenue growth and EBITDA margin targets all revised upward, making this a clear bullish catalyst.